Potential Antidepressive Effects of R-ketamine in Patients with Treatment Resistance Depression

Summary

R-ketamine shows potential as a treatment for treatment-resistant depression (TRD) based on pre-clinical studies, suggesting it may be more effective and safer than S-ketamine. However, clinical trials have not shown significant antidepressant effects from R-ketamine, despite its promising safety profile. This indicates that while R-ketamine has advantages in theory, its effectiveness in real-world settings remains uncertain.

Study at a glance

Abstract

Ketamine has a long history as an anesthetic but has recently demonstrated antidepressant effects at sub-anesthetic doses (Matveychuk et al., 2020). For individuals with treatment-resistant depression (TRD), typical antidepressants are frequently ineffective, whereas ketamine’s unique mechanisms have demonstrated promising results in reducing depressive symptoms where other treatments have failed (Voineskos et al., 2020; Matveychuk et al., 2020). Pre-clinical investigation of the ketamine enantiomers, R- and S-ketamine, revealed that R-ketamine may be more effective than S-ketamine due to its rapid-acting, long-lasting antidepressant-like effects with fewer psychotomimetic side effects and abuse liability (Chang et al., 2019; Yang et al., 2015; Bonaventura et al., 2021; Koncz et al., 2023). However, early clinical trials assessing R-ketamine to treat TRD have not yet produced significant antidepressant effects despite promising safety and tolerability profiles (Leal et al., 2023). This review compares the antidepressant efficacy, abuse liability, and safety profiles of ketamine enantiomers, focusing on the antidepressant success of R-ketamine in pre-clinical and clinical trials for TRD. Although R-ketamine did present promising results for treating TRD in pre-clinical trials, it did not demonstrate consistent significant antidepressant effects in clinical trials, making it difficult to conclude its effects in treating depression.

Tags